Skip to main content
Premium Trial:

Request an Annual Quote

Decode Logs 13-Percent Drop in Q4 Revenues Amid Swelling R&D Costs and Loss

NEW YORK, March 7 (GenomeWeb News) - Decode Genetics yesterday reported an approximately 13-percent decrease in revenues amid escalating losses for the fourth quarter.


Decode's revenues for the three months ended Dec.31, 2005, dropped to $9.8 million from $11.2 million year over year.


Research and development expenses increased nearly 60 percent to $13.7 million for the fourth quarter from $8.7 million for the same period in 2004, Decode said, primarily to support its drug-development programs.


The company's net loss grew to $21.1 million from $19.4 million in the year-ago period. Decode attributed the spike in net loss to the increased R&D expenses.


Decode had $155.6 million in cash and investments on hand asof Dec. 31.